|
|
|
|
|
|
The Company offers a broad range of clinical laboratory services including the Oncotech EDR® Assay and molecular biomarker testing. By utilizing proprietary Locked Nucleic Acids (LNA™) technology and miRNA biomarkers, Exiqon Diagnostics is establishing the next generation of molecular diagnostics for oncology. Exiqon Diagnostics has performed oncology services for more than 100,000 cancer patients from over 1,000 hospitals throughout North America and Europe. Exiqon Diagnostics is the trade name for Oncotech, Inc., a wholly owned subsidiary of Exiqon A/S.
|
|
|
|
|
| |
Innovative Molecular Oncology Testing Services for the Benefit of Cancer Patients. Exiqon Diagnostics, a wholly owned subsidiary of Exiqon A/S, is a leader in personalizing medicine for cancer patients. Exiqon Diagnostics is dedicated to developing and performing novel molecular and cell-based oncology assays to help physicians individualize and optimize treatment selection for their patients.
ONCOTECH is now Exiqon Diagnostics! To read more about the announcement, please click here.
To view the customer notification letter, please click here.
For a list of Customer FAQs regarding the transition, please click here.
| |
|
|
|
|
|